Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications-Reference-Cited by-同舟云学术

Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications

Published:2000-09 Issue:9 Volume:17 Page:650-656
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet Med

Author:

Chiarelli F.,Spagnoli A.,Basciani F.,Tumini S.,Mezzetti A.,Cipollone F.,Cuccurullo F.,Morgese G.,Verrotti A.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1464-5491.2000.00350.x/fullpdf

Reference43 articles.

1. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

2. Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen

3. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line.

4. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Thyroiditis on the Immune Profile in Young Patients with Uncomplicated Type 1 Diabetes;International Journal of Molecular Sciences;2024-09-08

2. Lower Risk of Incident Cataracts and Diabetic Retinopathy amongst Individuals Treated with Sodium Glucose Cotransporter-2 Inhibitor Compared to Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Mellitus;2024-03-27

3. Nailfold capillaroscopy shows microvascular dysfunction in children and adolescents with poorly controlled type 1 diabetes and normal retinal assessment;Minerva Pediatrics;2023-11

4. The Relationship between TNF-a, IL-35, VEGF and Cutaneous Microvascular Dysfunction in Young Patients with Uncomplicated Type 1 Diabetes;Biomedicines;2023-10-22

5. Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders;Frontiers in Endocrinology;2023-06-20